Show simple item record

dc.contributor.authorFerlazzo, G
dc.contributor.authorMohr, E
dc.contributor.authorLaxmeshwar, C
dc.contributor.authorHewison, C
dc.contributor.authorHughes, J
dc.contributor.authorJonckheere, S
dc.contributor.authorKhachatryan, N
dc.contributor.authorDe Avezedo, V
dc.contributor.authorEgazaryan, L
dc.contributor.authorShroufi, A
dc.contributor.authorKalon, S
dc.contributor.authorCox, H
dc.contributor.authorFurin, J
dc.contributor.authorIsaakidis, P
dc.date.accessioned2018-03-09T15:47:19Z
dc.date.available2018-03-09T15:47:19Z
dc.date.issued2018-02-13
dc.date.submitted2018-02-22
dc.identifier.citationEarly safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. 2018 Lancet Infect Disen
dc.identifier.issn1474-4457
dc.identifier.pmid29452942
dc.identifier.doi10.1016/S1473-3099(18)30100-2
dc.identifier.urihttp://hdl.handle.net/10144/619082
dc.description.abstractBedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa.
dc.language.isoenen
dc.publisherElsevieren
dc.rightsArchived with thanks to The Lancet. Infectious Diseasesen
dc.titleEarly safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort studyen
dc.identifier.journalThe Lancet. Infectious Diseasesen
refterms.dateFOA2019-03-04T13:46:14Z
html.description.abstractBedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients have been unable to access the two drugs in combination. Médecins Sans Frontières has supported the use of combination bedaquiline and delamanid for people with few treatment options since 2016. We describe early safety and efficacy of regimens containing the bedaquiline and delamanid combination in patients with drug-resistant tuberculosis in Yerevan, Armenia; Mumbai, India; and Khayelitsha, South Africa.


Files in this item

Thumbnail
Name:
Ferlazzo et al - 2018 - Early ...
Size:
336.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record